Figure 2.
Progression free survival time for the ITT population of patients randomized to receive (red) Cilengitide (600 mg/m2) and gemcitabine (1000 mg/m2) or (blue) gemcitabine alone (1000 mg/m2).
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.